Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03721016 · ClinicalTrials.gov registry record · Phase 3
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
A Phase 3 study, sponsored by Medy-Tox.
- Completed
- Registry status
- Phase 3
- Development phase
- 415
- Enrollment target
NCT03721016: Completed Phase 3 study, sponsored by Medy-Tox.
NCT03721016 is a Phase 3 study that has completed, run by Medy-Tox. The registered enrollment target is 415 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03721016, a Phase 3 study, has completed, sponsored by Medy-Tox.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 415 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
Primary Outcome
The outcome measured is the percentage of participants with a ≥ 2-grade improvement from baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) according to investigator and participant assessments of Glabellar Lines (GL) severity at maximum frown at Day 30. The investigator and participant evaluates the participant's GL severity using a Facial Wrinkle Scale With Photonumeric Guide (FWS) at maximum frown on Day 30. The scale ranges from (0 to 3) where 0=none and 3 = severe.
Interventions
- DRUG Placebo
- DRUG MT10109L
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2018-10-26 |
| Est. Completion | 2021-01-22 |
| Phase | Phase 3 |
What the finished NCT03721016 record still lists
NCT03721016 is an interventional study that assigns participants to a tested intervention. The registered 415 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03721016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03721016 about?
NCT03721016 is a clinical study titled "MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)". To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.
What is the current status of trial NCT03721016?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 415 participants. The study started on 2018-10-26. Estimated completion is 2021-01-22.
What interventions are being tested in trial NCT03721016?
The interventions under investigation include: Placebo (DRUG), MT10109L (DRUG).
Who is sponsoring clinical trial NCT03721016?
This trial is sponsored by Medy-Tox, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03721016's enrollment target sits among peer trials
415 903rd of 2000 higher than 1,096 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI